Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$5.14 +14.7%	$5.27	$2.34 ▼ $8.79	$185.16M	N/A	218,250 shs	349,421 shs
FEMY Femasys	$1.24	$1.39	$0.86 ▼ $1.80	$33.67M	-2.55	236,300 shs	111,123 shs
LUCD Lucid Diagnostics	$1.33 +3.1%	$1.41	$0.63 ▼ $1.80	$120.70M	1.26	459,153 shs	1.90 million shs
OBIO Orchestra BioMed	$2.58 -9.5%	$3.83	$2.49 ▼ $8.87	$98.85M	0.62	146,549 shs	303,863 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	+14.73%	+78.47%	+4.47%	-14.19%	+513,999,900.00%
FEMY Femasys	0.00%	0.00%	-22.50%	+7.83%	-6.77%
LUCD Lucid Diagnostics	+3.10%	+9.92%	-14.19%	+47.94%	+94.70%
OBIO Orchestra BioMed	-9.47%	-9.47%	-41.89%	-51.59%	-42.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FEMY Femasys	2.0416 of 5 stars	3.5	2.0	0.0	0.0	1.1	2.5	0.6
LUCD Lucid Diagnostics	2.4545 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.6
OBIO Orchestra BioMed	1.7338 of 5 stars	3.6	2.0	0.0	0.0	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	221.01% Upside
FEMY Femasys	3.00	Buy	$11.50	827.42% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.50	163.16% Upside
OBIO Orchestra BioMed	3.20	Buy	$15.00	481.40% Upside

Current Analyst Ratings Breakdown

Latest FEMY, LUCD, OBIO, and AVR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/4/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
4/3/2025	OBIO Orchestra BioMed	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/1/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	FEMY Femasys	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
3/25/2025	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/24/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.50 ➝ $3.00
3/20/2025	OBIO Orchestra BioMed	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.71M	68.30	N/A	N/A	N/A	∞
FEMY Femasys	$1.63M	20.67	N/A	N/A	$0.85 per share	1.46
LUCD Lucid Diagnostics	$4.35M	27.77	N/A	N/A	($0.47) per share	-2.83
OBIO Orchestra BioMed	$2.64M	37.47	N/A	N/A	$1.90 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
FEMY Femasys	-$14.25M	-$0.85	N/A	N/A	N/A	-1,435.77%	-141.49%	-82.30%	5/8/2025 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.08	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	5/12/2025 (Estimated)
OBIO Orchestra BioMed	-$49.12M	-$1.67	N/A	N/A	N/A	-2,179.33%	-107.04%	-70.88%	5/12/2025 (Estimated)

Latest FEMY, LUCD, OBIO, and AVR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LUCD Lucid Diagnostics	-$0.13	N/A	N/A	N/A	$1.30 million	N/A
5/8/2025	N/A	FEMY Femasys	-$0.17	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million
3/27/2025	Q4 2024	FEMY Femasys	-$0.25	-$0.23	+$0.02	-$0.23	$1.66 million	$0.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	N/A	N/A
FEMY Femasys	0.86	3.94	3.26
LUCD Lucid Diagnostics	N/A	1.18	1.14
OBIO Orchestra BioMed	N/A	4.23	4.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
FEMY Femasys	65.27%
LUCD Lucid Diagnostics	74.01%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	N/A
FEMY Femasys	12.32%
LUCD Lucid Diagnostics	8.80%
OBIO Orchestra BioMed	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	36.02 million	N/A	N/A
FEMY Femasys	30	27.15 million	20.08 million	Not Optionable
LUCD Lucid Diagnostics	70	90.75 million	54.12 million	No Data
OBIO Orchestra BioMed	4	38.31 million	35.47 million	Not Optionable

FEMY, LUCD, OBIO, and AVR Headlines

Recent News About These Companies

Orchestra BioMed (NASDAQ:OBIO) Given Buy Rating at Chardan Capital

April 24 at 3:07 PM | marketbeat.com

Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025

April 24 at 8:19 AM | msn.com

Orchestra BioMed (NASDAQ:OBIO) Earns "Buy" Rating from Chardan Capital

April 24 at 2:47 AM | americanbankingnews.com

Orchestra BioMed announces AVIM therapy-focused satellite symposium at HRS 2025

April 23 at 9:00 PM | markets.businessinsider.com

Orchestra BioMed granted breakthrough device designation, says H.C. Wainwright

April 23 at 9:00 PM | markets.businessinsider.com

Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy

April 23 at 4:00 PM | msn.com

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

April 23 at 9:00 AM | globenewswire.com

Orchestra Biomed wins FDA breakthrough nod for hypertension treatment

April 22 at 2:45 PM | massdevice.com

Orchestra BioMed shares surge on FDA breakthrough designation

April 22 at 9:45 AM | in.investing.com

Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension

April 22 at 7:15 AM | quiverquant.com

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

April 22 at 7:00 AM | globenewswire.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Down 6.04%

April 15, 2025 | aaii.com

What is B. Riley's Estimate for OBIO Q1 Earnings?

April 8, 2025 | marketbeat.com

Chardan Capital Has Strong Outlook for OBIO FY2025 Earnings

April 8, 2025 | marketbeat.com

Orchestra BioMed (NASDAQ:OBIO) Upgraded by B. Riley to "Strong-Buy" Rating

April 7, 2025 | marketbeat.com

Orchestra BioMed (NASDAQ:OBIO) Given New $12.00 Price Target at HC Wainwright

April 6, 2025 | marketbeat.com

Orchestra BioMed price target lowered to $12 from $14 at H.C. Wainwright

April 5, 2025 | markets.businessinsider.com

4OBIO : Where Orchestra BioMed Hldgs Stands With Analysts

April 4, 2025 | benzinga.com

Orchestra BioMed's (OBIO) Buy Rating Reiterated at Chardan Capital

April 4, 2025 | marketbeat.com

Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy

April 2, 2025 | msn.com

Orchestra BioMed (NASDAQ:OBIO) Posts Earnings Results, Hits Estimates

April 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY, LUCD, OBIO, and AVR Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$5.14 +0.66 (+14.73%)

As of 04/24/2025 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Femasys NASDAQ:FEMY

$1.24 0.00 (0.00%)

As of 04/24/2025 04:00 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Lucid Diagnostics NASDAQ:LUCD

$1.33 +0.04 (+3.10%)

As of 04/24/2025 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Orchestra BioMed NASDAQ:OBIO

$2.58 -0.27 (-9.47%)

As of 04/24/2025 04:00 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time